Their invention, initial authorization and later approval signaled ... For now, HHS appears to be retreating primarily from ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 30, 2025 /PRNewswire/ -- BioVaxys Technology ...

New research in Sweden has produced a "blueprint" revealing how the human heart is built during prenatal development. It ...

Under the bright lights of Durban’s convention centre, amid applause from scientists and policymakers gathered for the 4th ...

It’s notoriously tough to land a political blow on Donald Trump, but California congressman Ro Khanna is one of the few ...

The Needle-Free Injection System Market represents a groundbreaking advancement in medical technology, offering an innovative ...

High-fidelity visualization of a fetal heart is essential for deep understanding about heart myofibers orientation and the ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an increase to its non-brokered ...

The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to ...

New research in Sweden has produced a "blueprint" revealing how the human heart is built during prenatal development.

Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®?(Dengue ...